SQLite Web: event

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt","company":"TREACE MEDICAL CONCEPTS, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1c6f9d8b24545064","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:26:47.086862+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt","source_event_id":"evt_ef2bc9693fc8","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"8d5b0fc21a3ff0c9","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-08","2026-04-09","2027-01-31","2026"],"entities":[{"asset_class":"equity","name":"TREACE MEDICAL CONCEPTS, INC.","relevance":"high","symbol":"TMCI","type":"issuer"},{"asset_class":"other","name":"Gaetano M. Guglielmino","relevance":"high","symbol":"","type":"person"},{"asset_class":"other","name":"John T. Treace","relevance":"medium","symbol":"","type":"person"}],"event_type":"earnings","information_gaps":["The excerpt does not include the full text of Item 7.01 \u201cPreliminary, Unaudited First Quarter Outlook,\u201d so specific financial outlook numbers are not provided here.","The excerpt is truncated near the end (\u201cexpects to file as an exhibit to its Quarterly Repor\u201d), so the exhibit filing timing/details are incomplete.","No prior-known state is provided in the prompt, so the exact \u201cdelta vs prior\u201d cannot be determined beyond what is newly disclosed in this 8-K excerpt."],"key_facts":["The company filed a Form 8-K with a date of report of April 8, 2026.","Item 2.02 states that information in Item 7.01 under the heading \u201cPreliminary, Unaudited First Quarter Outlook\u201d is incorporated by reference into Item 2.02.","Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer, will depart from the company.","The company does not plan to fill the Chief Commercial Officer role.","Mr. Guglielmino\u2019s responsibilities will be assumed by existing employees; the Senior Vice President, Sales will report directly to CEO John T. Treace.","Mr. Guglielmino\u2019s departure is stated to not be the result of any dispute or disagreement with the company relating to operations, policies, or practices.","A Consulting Services Agreement is effective April 9, 2026 and provides service through January 31, 2027.","Under the Consulting Services Agreement, Mr. Guglielmino will receive: (1) monthly fee of $36,666.67; (2) payment of COBRA premiums; (3) pro-rated annual target bonus based on days served in 2026, payable when annual bonuses are generally paid to employees; (4) payment for rent on his Ponte Vedra apartment until the lease is assigned to the company; and (5) continued vesting in previously-granted equity awards per their terms.","Mr. Guglielmino signed a release of claims in favor of the company and an attestation that his confidentiality, nonsolicitation, and noncompetition agreement is in effect and enforceable.","The company expects to file the Consulting Services Agreement as an exhibit to its Quarterly Report (text is truncated at the end of the provided excerpt)."],"numeric_claims":[{"label":"monthly consulting fee ($)","value":"36,666.67"},{"label":"consulting term end date","value":"2027-01-31"},{"label":"consulting agreement effective date","value":"2026-04-09"},{"label":"departure effective date (close of business)","value":"2026-04-08"}],"primary_claim":"Effective April 8, 2026, Gaetano M. Guglielmino will depart as Chief Commercial Officer, the role will not be filled, and he will transition via a consulting agreement effective April 9, 2026 through January 31, 2027 with specified compensation terms.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Treace Medical Concepts, Inc. filed a Form 8-K reporting (i) Item 2.02 results/financial condition information that incorporates by reference Item 7.01 \u201cPreliminary, Unaudited First Quarter Outlook,\u201d and (ii) the effective departure of its Chief Commercial Officer, Gaetano M. Guglielmino, with transition arrangements and a consulting agreement.","topics":["Form 8-K","Item 2.02","Preliminary, Unaudited First Quarter Outlook","Chief Commercial Officer departure","Consulting Services Agreement","executive transition","compensation and benefits"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 TREACE MEDICAL CONCEPTS, INC. \u00b7 Filed 20260409","ticker":"TMCI","tickers":["TMCI"],"title":"TMCI filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000010.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — signals

Update row sig_c4b146a0dd7a in signals